Explanipedia

Association of Plasma Placental Growth Factor with White Matter Hyperintensities in Alzheimer’s Disease Open

Kazuya Igarashi, Tamao Tsukie, Kazuo Washiyama, Kiyoshi Onda, Yasuo Miyagi , et al. · 2025

Autopsy studies have shown that Alzheimer’s disease (AD) often coexists with cerebrovascular injury, affecting cognitive outcomes and the effectiveness of anti-amyloid-beta (Aβ) drugs. No fluid biomarkers of cerebrovascular injury have bee…

Association of plasma placental growth factor with white matter hyperintensities in Alzheimer’s disease Open

Kazuya Igarashi, Tamao Tsukie, Kazuo Washiyama, Kiyoshi Onda, Yasuo Miyagi , et al. · 2025

Background The global prevalence of dementia, particularly Alzheimer’s disease (AD), is increasing. With the introduction of anti-β-amyloid (Aβ) antibody drugs, the accurate in vivo diagnosis of AD has become crucial. Autopsy studies have …

Association of rare APOE missense variants with Alzheimer's disease in the Japanese population Open

Akinori Miyashita, Ai Obinata, Norikazu Hara, Risa Mitsumori, Daita Kaneda , et al. · 2025

Background Little is known about the rare missense variants (RMVs) of APOE in East Asians, including the Japanese, and their association with Alzheimer's disease (AD) and lipid metabolism. Objective To identify APOE RMVs in the Japanese po…

Clinical utility of CSF Aβ38 in Japanese research and clinical cohorts Open

Tamao Tsukie, Kensaku Kasuga, Masataka Kikuchi, Takanobu Ishiguro, Akinori Miyashita , et al. · 2025

INTRODUCTION Previous studies have reported that cerebrospinal fluid (CSF) amyloid beta (Aβ42/Aβ38) performs comparably to Aβ42/Aβ40 in predicting amyloid positron emission tomography (PET) positivity in White cohorts. However, this findin…

CSF α‐synuclein reflects neurodegeneration in Alzhiemer's disease Open

Kazuya Igarashi, Kensaku Kasuga, Tamao Tsukie, Masataka Kikuchi, Akinori Miyashita , et al. · 2024

Background The aim of this study is to investigate the clinical significance of cerebrospinal fluid (CSF) α‐synuclein (αSyn), a presynaptic protein, in Alzheimer's disease (AD) continuum. Method We analyzed 177 CSF samples obtained from pa…

Application of blood biomarkers for the future anti‐Aβ antibody therapy in Japan Open

Kensaku Kasuga, Tamao Tsukie, Kazuya Igarashi, Takanobu Ishiguro, Akinori Miyashita , et al. · 2024

Background With the approval of Lecanemab in Japan following the U.S., biomarker‐based diagnosis of AD will be required in daily practice. However, PET or CSF are limited by cost, low availability, and invasiveness. In addition, frequent M…

Clinical Characteristics of Progressive Supranuclear Palsy Subtypes Defined by AT(N) CSF Biomarkers Open

Takanobu Ishiguro, Kensaku Kasuga, Tamao Tsukie, Osamu Onodera, Takeshi Ikeuchi · 2024

Background Progressive supranuclear palsy (PSP) may show concomitant neuropathological findings such as Alzheimer's disease (AD)‐related pathologies. Recent advances in CSF biomarkers enabled the estimation of neuropathological changes in …

APOE rare missense variants in Japan Open

Akinori Miyashita, Norikazu Hara, Ai Obinata, Tamao Tsukie, M. Hasegawa , et al. · 2024

Background APOE is well recognized to be the most influential susceptibility gene for Alzheimer’s disease (AD). For the wild‐type allele, e3 , it is known that the e4 allele is a risk for AD, while the e2 allele is protective. Recently, ge…

Association of rareAPOEmissense variants with Alzheimer's disease in the Japanese population Open

Akinori Miyashita, Ai Obinata, Norikazu Hara, Risa Mitsumori, Daita Kaneda , et al. · 2024

Background: APOE is a major susceptibility gene for Alzheimer's disease (AD). Recent studies in Europe and the US have identified rare missense variants (RMVs) in APOE which are significantly associated with AD. However, little is known re…

Application of AT(N) classification using two CSF A‐markers and two CSF N‐markers to Alzheimer’s Clinical Syndrome (ACS) and non‐ACS Open

Kensaku Kasuga, Tamao Tsukie, Masataka Kikuchi, Takanobu Ishiguro, Takayoshi Tokutake , et al. · 2023

Background Cerebrospinal fluid (CSF) biomarkers reflect the pathological process underlying Alzheimer’s disease (AD) and improve the accuracy of AD diagnosis. AT(N) classification using these CSF biomarkers has been used within the researc…

AT(N) Classification and Clinical Characterization by CSF Biomarkers in Patients with Corticobasal Syndrome Open

Takanobu Ishiguro, Kensaku Kasuga, Takayoshi Tokutake, Tamao Tsukie, Takuya Konno , et al. · 2023

Background Corticobasal syndrome (CBS) is clinically characterized by asymmetric cortical and extrapyramidal deficits. CBS is caused by various pathological conditions including primary tauopathy and Alzheimer’s disease (AD). To clarify wh…

The clinical application of optimized AT(N) classification in Alzheimer’s clinical syndrome (ACS) and non-ACS conditions Open

Kensaku Kasuga, Tamao Tsukie, Masataka Kikuchi, Takayoshi Tokutake, Kazuo Washiyama , et al. · 2023

We aimed to assess the utility of AT(N) classification in clinical practice. We measured the cerebrospinal fluid levels of amyloid-β (Aβ) 42, Aβ40, phosphorylated tau, total tau, and neurofilament light chain (NfL) in samples from 230 pati…

The Clinical Application of Optimized AT(N) Classification in Alzheimer’s Clinical Syndrome (ACS) and non-ACS Conditions Open

Kensaku Kasuga, Tamao Tsukie, Masataka Kikuchi, Takayoshi Tokutake, Kazuo Washiyama , et al. · 2022

Background Cerebrospinal fluid (CSF) biomarkers reflect the pathological process underlying Alzheimer’s disease (AD) and improve the accuracy of AD diagnosis. AT(N) classification using these CSF biomarkers was applied to define AD continu…

Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid Open

Kensaku Kasuga, Masataka Kikuchi, Tamao Tsukie, Kazushi Suzuki, Ryoko Ihara , et al. · 2022

Background The AT(N) classification was proposed for categorising individuals according to biomarkers. However, AT(N) profiles may vary depending on the markers chosen and the target population. Methods We stratified 177 individuals who pa…

Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy Open

Takayoshi Tokutake, Kensaku Kasuga, Tamao Tsukie, Takanobu Ishiguro, Takayoshi Shimohata , et al. · 2022

Our results suggest CSF levels of NG2 and NfL as possible diagnostic and prognostic biomarkers in MSA. Further study is necessary to validate these findings.

Effects of an essential amino acid mixture on behavioral and psychological symptoms of dementia and executive function in patients with Alzheimer's disease: A double‐blind, randomized, placebo‐controlled exploratory clinical trial Open

Michihiro Takada, Shin Tanaka, Koh Tanaka, Tamao Tsukie, Masako Tsukamoto‐Yasui , et al. · 2022

Background The increasing number of dementia patients has become a global social problem. Amino acids are known to be used as precursors of neurotransmitters in the brain. Amino acid mixtures as a supplement may be used as a solution to Al…

Correlated levels of cerebrospinal fluid pathogenic proteins in drug‐naïve Parkinson's disease Open

Kenjiro Ono, Hidetomo Murakami, Omar M. A. El‐Agnaf, Takahiko Tokuda, Takuma Ohmichi , et al. · 2020

Background Toxic oligomeric α‐synuclein (αS; O‐αS) has been suggested to play a central role in the pathogenesis of Lewy body diseases such as Parkinson's disease (PD). Cerebrospinal fluid (CSF) levels of αS, O‐αS, total and phosphorylated…

P1‐233: CSF BIOMARKERS OF ALZHEIMER'S CLINICAL SYNDROME Open

Kensaku Kasuga, Tamao Tsukie, Takayoshi Tokutake, Yo Higuchi, Takanobu Ishiguro , et al. · 2019

It has been shown that cerebrospinal fluid (CSF) β-amyloid1-42 (Aβ1-42) levels show an inverse correlation with brain amyloid plaques, whereas total tau (t-tau) and phosphorylated tau (p-tau) levels correlate with the number of neurofibril…

Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease Open

Hidetomo Murakami, Takahiko Tokuda, Omar M. A. El‐Agnaf, Takuma Ohmichi, Ayako Miki , et al. · 2019

CSF levels of αS are correlated with some clinical symptoms and CSF levels of other pathogenic proteins in drug-naïve PD patients. These correlations suggest a central role for interaction and aggregation of αS with Aβ1-42, tau, and phosph…

Additional file 1: of Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease Open

Hidetomo Murakami, Takahiko Tokuda, Omar M. A. El‐Agnaf, Takuma Ohmichi, Ayako Miki , et al. · 2019

All data used during this study. (XLSX 13 kb)

Longitudinal clinical and neuro-radiological findings in a patient with leukoencephalopathy with brain calcifications and cysts (Labrune syndrome) Open

Yasushi Iwasaki, Kenichiro Hoshino, Keiko Mori, Masumi Ito, Yoshinari Kawai , et al. · 2017

P2‐172: Transcriptome Profile of Peripheral Blood from Patients with Alzheimer's Disease by Rna‐Seq Analysis Open

Norikazu Hara, Naomi Mezaki, Takeshi Miura, Kensaku Kasuga, Tamao Tsukie , et al. · 2016

There is growing demand for blood-based biomarkers for neurodegenerative dementias including Alzheimer’s disease (AD), because blood sampling is less invasive and easily available. Enrollment of qualified participants into clinical trials …

Systematic review and meta-analysis of Japanese familial Alzheimer’s disease and FTDP-17 Open

Kensaku Kasuga, Masataka Kikuchi, Takayoshi Tokutake, Akihiro Nakaya, Toshiyuki Tezuka , et al. · 2015

Mutations in APP, PSEN1 and PSEN2 as the genetic causes of familial Alzheimer's disease (FAD) have been found in various ethnic populations. A substantial number of FAD pedigrees with mutations have been reported in the Japanese population…

Tamao Tsukie YOU? Author Swipe